Premium
Effects of simvastatin on blood lipids, von Willebrand factor and endothelin in coronary heart disease
Author(s) -
Qi YaLing,
Zhao WenJie,
Yang LiMin,
Yang ZhiMing,
Kang∗ YuMing
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a851
Subject(s) - simvastatin , medicine , endocrinology , von willebrand factor , creatinine , cholesterol , blood urea nitrogen , blood lipids , creatine , lipoprotein , renal function , creatine kinase , platelet
The present study was undertaken to investigate effects of simvastatin on blood lipids, von Willebrand factor (vWF) and endothelin (ET) in coronary heart disease (CHD). Thirty CHD patients associated with hyperlipemia were treated with oral simvastatin (20mg/day for 4 weeks). Serum levels of total cholesterol, low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol, high sensitivity C reactive protein, vWF and ET were measured. After treatment with simvastatin, serum levels of total cholesterol (4.45±0.67 vs 5.50±0.78 mmol/L, post‐treatment vs pre‐treatment, P<0.01), LDL‐C (2.68 ±0.67 vs 3.38±0.70 mmol/L, post‐treatment vs pre‐treatment, P<0.01), high sensitivity C reactive protein (9.34± 0.68 vs 10.60±0.86 mg/ml, post‐treatment vs pre‐treatment, P<0.01), vWF (101.93±14.12 vs 129.11±14.36 IU/dl, post‐treatment vs pre‐treatment, P<0.05) and ET (49.85±20.42 vs 61.83±23.94 μg/L, post‐treatment vs pre‐treatment, P<0.01) were decreased, and high density lipoprotein cholesterol was increased compared with the baseline before treatment (pre‐treatment). In order to observe the effects of simvastatin on hepatic and renal function, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine and creatine kinase were assayed, and the results indicated that these indicators of hepatic and renal function were unaffected. Conclusion: Simvastatin decreased serum levels of blood lipids, and simvastatin inhibited vWF which was involved in the coagulation response. Simvastatin inhibited blood vessel contraction by decreasing the expression of ET.